KUROS N news, videos and press releases - Page 2
For more news please use our advanced search feature.
KUROS N - More news...
KUROS N - More news...
- Kuros Biosciences Receives FDA Clearance for Use of MagnetOs in Interbody Spinal Cages
- Kuros reports a 150% increase in direct MagnetOs sales in the first nine months of 2023 and announces changes within the Executive Management
- Kuros Reports a 150% Increase in Direct MagnetOs Sales in the First Nine Months of 2023 and Announces Changes Within the Executive Management
- Kuros Biosciences Reports Results for First Half 2023
- Kuros Biosciences Announces Completion of Enrollment in the Fibrin-PTH Phase 2 Trial
- Annual General Meeting of Kuros Biosciences approves all resolutions
- Kuros reports 168% increase in direct MagnetOs sales in the first quarter of 2023
- Kuros Biosciences reports results for the full year 2022
- Kuros Biosciences Announces Publication of Supportive Osteoimmunology Data for MagnetOs Bone Graft
- Kuros Biosciences Announces Changes to Executive Management Team
- Kuros Biosciences Completes Enrollment of Randomized Stage of Phase 2 Trial for Fibrin-PTH
- Kuros Biosciences completes enrolment in Level 1 clinical study of MagnetOs Granules
- Kuros reports 73% increase in MagnetOs sales in first nine months of 2022
- Kuros Biosciences awarded 2022 Spine Technology Award for MagnetOs Flex Matrix by Orthopedics This Week
- Kuros Biosciences to present positive clinical data for MagnetOs at NASS 2022 Annual Meeting
- Kuros Biosciences to present positive clinical data for MagnetOs at NASS 2022 Annual Meeting
- Kuros Biosciences Appoints Chris Fair as Chief Operating Officer
- Kuros Biosciences announces successful CHF 6.0 million private placement
- Kuros Biosciences’ MagnetOs Bone Graft Successfully Achieves Three Key Milestones
- Kuros Biosciences reports results for the first six months of 2022
- Annual General Meeting of Kuros Biosciences approves all resolutions
- Kuros Biosciences: Completion of the acquisition of Checkmate Pharmaceuticals by Regeneron Pharmaceuticals triggers a $5 million milestone payment
- Kuros Biosciences: Completion of the Acquisition of Checkmate Pharmaceuticals by Regeneron Pharmaceuticals Triggers a $5 Million Milestone Payment
- Kuros Biosciences announces favorable preliminary results of MagnetOs as standalone alternative to autograft in first randomized controlled trial
- Kuros Biosciences announces commercial launch of MagnetOs Easypack Putty in the U.S.
- Kuros Biosciences continues strong commercial roll-out of MagnetOs bone graft
- Kuros Biosciences's MagnetOs Flex Matrix Cleared by FDA for Spinal Indications
- Kuros Biosciences reports results for the full year 2021
- Kuros Biosciences's MagnetOs Granules cleared by FDA for expanded spinal indications
- Kuros Biosciences publishes first-in-human clinical data for Fibrin-PTH (KUR-113) in treatment of open tibial shaft fractures
